|31st December 2020||Gary Sender||32||Payment by withholding||$2.42||$77.44|
|17th December 2020||Charles A Jr Rowland||10,909||Open or private sale||$117.82||$1,285,298.38|
|17th December 2020||Charles A Jr Rowland||10,909||Exercise of derivative||$19.53||$213,052.77|
|7th December 2020||Carrie L. Bourdow||132,934||Payment by withholding||$2.27||$301,760.18|
|30th November 2020||Robert Crotty||368||Payment by withholding||$0.43||$157.14|
|30th November 2020||Steven P. Gelone||628||Payment by withholding||$0.43||$268.16|
|30th November 2020||Jennifer Schranz||301||Payment by withholding||$0.43||$128.53|
|30th November 2020||Theodore R Schroeder||1,211||Payment by withholding||$0.43||$517.10|
|30th November 2020||Gary Sender||312||Payment by withholding||$0.43||$133.22|
|3rd November 2020||Charles A Jr Rowland||694||Open or private sale||$95.97||$66,603.18|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company. It engages in the research and development of novel antibiotics to treat serious infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.